MassCONNECT

Leveraging industry networks to

advance translational research
 The goal of translational medicine…

Industr Bedside Bench

y

AMC/Uni
v

Late-preclinical
Clinical trials &
Preclinical dev

Clinical
development
 Pharma’s predicament

50 60
R&D expenditures
NMEs and Biologics Approved

R&D Spending (US$ Billions)

Approvals 50
40

40
30
30
20
20

10
10

1995 2000 2005 Courtesy of Ted Torphy, JNJ

Sources: FDA/CDER, PhRMA, PricewaterhouseCoopers presented at Massbio Pharma
Note: R&D spending from non-PhRMA companies not available Days
Translating research to products

“Applied”
research

Phase II-Proof
of concept

FIM
Value

Proof of
principle
$

Animal
Translation
disease gap
model

Basic
Invention = data, RO1 funding enabled
research
tools, IP, Know- research
How

Research
progress
 But the goal is impeded by translation gap!

Commerci
al-ization
Value
$
Industrializati
on
MassCONNE
CT Translation Gap
Inability to effectively convert
Discovery accomplishments achieved in the
academic labs to the parlance of
work early stage pipeline opportunity
Poor networks of expertise,
funding, and industry leadership
 impedes transfer of value
between academia and
Time biotech/pharma
Leveraging the industry accelerates the
right opportunities

– Build a cross-disciplinary group of advisors and

mentors
• provide tutoring and advice to diminish obstacles
which derail promising early-stage technology prior to
commercialization
– Rapidly screen technology to identify the most
promising candidates
– Connect proven industry navigators & advisors
What’s in it for you…power of distributive tasking
Distributive tasking from industry professionals
allows more opportunities to be examined,
sorted and prioritized

• Using seasoned industry professionals to sift

through and prioritize opportunities of value
• Helps you prioritize opportunities with greatest
likelihood of success
• Capitalize on the industry network to target the
parties most interested in licensing
•Increase the throughput of technology out of
your office
 Accelerating the right opportunities

Technology Scouting
+ Innovator Services = Products and Startups

Partnerships with
Industry
•Proof-of-concept
•Proof-of-concept
development
development
•Bridging
•Bridging the
the valley
valley of
of
death
death

Sources of Innovation •Disciplined

•Disciplined due
due diligence
diligence
Products & Startups
•Turn
•Turn science
science into
into products
products
•Technology Commercially
Commercially viable
viable
•Technology identification
identification
products
products to…
to…
•Investigator
•Investigator relationships
relationships
•Fill
•Fill bio/pharma
bio/pharma
•Technology
•Technology aggregation
aggregation pipelines
pipelines
•Conduct
•Conduct clinical
clinical
trials
trials
MassCONNECT ••Catalyze
Catalyze startups
startups
••Mentorship/Networking
Mentorship/Networking
••EIR
EIR program
program
•Workshops/training
•Workshops/training
••Sector
Sector experts
experts
••Due
Due diligence
diligence
••Grants/matching
Grants/matching funds
funds
Ideal investigator profile for MassCONNECT


 Entrepreneurial
Visionary
Collaborative
 “Next gen”
Exciting ideas
Lacking industry
relationships
“Quick and dirty” guide to attracting investors

• Technical POC that is differentiated

– In-vivo data (animal model)
• Have the animal model's data been repeated?
• Patents are available for exclusive licenses
• Publication in a peer reviewed technology journal
– Publications in strong journals
• ideal but not necessary
• Ability for platform development--->multiple targest (Dx or Thx)
– If not..., then:
• option 1: more likely to outlicense to big pharma or biotech
• option 2: get grant $ to show platform POC for 2nd target
• Validation from Industry experts regarding:
– promise/importance of technology
• supported by diligence with KOL

• Who could eat your lunch

– Evaluate 2-3 competing technologies, and provide an answer as to why yours is different
– Reasons to believe viability
“Quick and dirty” guide to attract pharma

Secret Sauce to attracting pharma?

Anything that pulls risk forward!

-Molecules (Thx/Dx)
-Validated
- Tools
- Biomarkers!
- Mice, cell based assays
- Abs, model molecules
- Predictive disease models
Accelerating proof-of-concept to partnerships

…commercially valuable the markets to which

and
university discoveries the discoveries apply

Early-stage Validated
Commercialization Gap
“The Valley of Death ”
Incomplete Unclear Ready to Clear
Technology Market Commer- Market
Validation Potential cialize Potential
MassCONNECT Value Proposition

 Demystify the translation gap

– Reveal where the gaps are and how to fill them
• Proof-of-concept studies
• Understand market (patient) needs
• Hurdles to commercialization de-risking opportunities
 Create high value linkage to industry
– Bio/pharma networks
– VC and other funding networks
 Accelerate a value stream for your technology
– Better licenses
– Potential start-up
 MassCONNECT delivers to you
Non-profit
presentatio
Submissio n
n Refinemen Output VC
Evaluation Refinemen Output
tt Developme
nt Corp

Improv 1-2x Corp Lic

e
Return to
Evaluation of business Academia
Screening of
proposal
technology
• Industry feedback on
strengths, weaknesses, Business advisors Introduction to funding
opportunity, threats work with investigators network
to coach
Free participation in
In hand:
MassBio Programs Concise business plan •Refined business pitch
•Entrepreneur’s University developed (by MBAs) deck
•BD Committee Meetings •Understanding of business
•Finance Committee model
Meetings Office Hours
•VCs- real time feedback •Strategy and operations
•MassBio – BD&L delineated
One-to-one •Mentor network resource
consultation with Creation of industry
industry expert network
 Pharma Days
Building productive partnerships

 A one to two day unique partnering event.

MassCONNECT
 Visibility + Accessability = Possibility
MassBio
Innovation  Industry sourcing strategy
Exchange
revealed
Pharma Days  One-on-one partnering with
Investors Forum heads of business development
Innovators’ at major bio/pharma
Roundtable
 Intimate and unhurried exchange
of information.
 Obviate the frenzy and “noise”
of other major partnering
conferences Best of all, Pharma Days is right
here in Cambridge! No need to
travel, take time out of your offices,
or waste time trying to find a time to
meet.
 MassBio Innovation Exchange

 Web 2.0 open innovation platform

 connects solutions to problems
 Couples technology and the networking power of
MassBio
 Tailors technology disclosures to industry “spec”
 Communication channel for accessed technology
You are cordially invited to apply for
participation in MassCONNECT.
 
http://www.massbio.org/membership/massconnect

Deadline April 16th , 2010

Have questions? Contact Imran Nasrullah, Chief

Business Officer at MassBio, at 617-674-5151.
Back up slides
Sustaining growth – Wall Street’s

• Consider Lipitor, in mid year

2008, its global sales were $12B
•Next year’s return needs to
be $1.2B
• A new product needs to
bring in $1.2B to keep EPS
up!
 Generally, limited resources hampers your
effectiveness
Investigator
pressure
Sifting for
valuable
disclosures
•Limited
throughput
•Lower value
licenses
•Longer
negotiation
Disclosed times
Opportunities Limited
resources for
due diligence
Staff:Disclosur
Limted e ratio is
Opportunities budgets small
 Innovators Roundtables
Solutions-based dialogue with leaders in industry and
stakeholders
 Exclusive roundtable discussions with leading academicians,
MassCONNECT
CEOs, R&D heads, angel investors, venture capitalists.
MassBio
Innovation
Exchange  The objective: define a set of initiatives, where participants can,
Pharma Days
directly or through influence, bring the necessary funding to
bear to assure that those early stage innovations with the
Investor Forum highest potential continue to the clinic, enrich pipelines and
Innovators’ improve options for patients.
Roundtable

 To devise better collaborative models to expedite translational

therapeutics.
 MassCONNECT Process
Non-profit
presentatio
Submissio n
n Output
Output VC
Evaluation Refinemen
Refinemen
tt Developme
nt Corp

Improv 1-2x Corp Lic

e
Return to
Business advisory Academia
One-to-one
services
consultation
MassBio Programs
MassBio Programs
Office Hours Network of funding
•Entrepreneur’s University
•VCs sources:
•BD Committee Meetings •VCs
•Finance Committee •MassBio – BD&L
•Drug development
Meetings •Business plan competition
One-to-one
Education Foundation consultation
Courses